Malaria

Current Opinion in Infectious Diseases

Volumn 16, Issue 5, 2003, Pages 389-395

  Maitland, Kathryn ^a,b,e   Bejon, Phillip ^a,c   Newton, Charles R J C ^a,d  

^a Ctr for Geogr Medicine Research   (Kenya)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e CGMRC KEMRI   (Kenya)

Author keywords

Internet; Malaria; Pathogenesis; Travel; Treatment; Vaccine

Indexed keywords

ACETYLCYSTEINE; ADRENALIN; ALANINE; ANTIMALARIAL AGENT; ATOVAQUONE PLUS PROGUANIL; DIAZEPAM; DICHLOROACETIC ACID; FOLIC ACID ANTAGONIST; FOSPHENYTOIN SODIUM; GLUTAMINE; MALARIA VACCINE; MEFLOQUINE; PHENOBARBITAL;

AMINO ACID METABOLISM; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDEMIC DISEASE; EXCHANGE BLOOD TRANSFUSION; HOSPITAL ADMISSION; HUMAN; MALARIA; MORBIDITY; MORTALITY; MOZAMBIQUE; NONHUMAN; PATHOGENESIS; PLASMODIUM FALCIPARUM; PROGNOSIS; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ACIDOSIS; ANTIMALARIALS; CLINICAL TRIALS; HUMANS; MALARIA; MALARIA VACCINES; WORLD HEALTH;

EID: 0142107383     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200310000-00004     Document Type: Review

References (66)

1. Gardner MJ, Hall N, Fung E, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002; 419:498-511. This study reports an analysis of the genome sequence of P. falciparum clone 3D7. The 23-megabase nuclear genome consists of 14 chromosomes, encodes approximately 5300 genes, and is the most (A + T)-rich genome sequenced to date.
2. Holt RA, Subramanian GM, Halpern A, et al. The genome sequence of the malaria mosquito Anopheles gambiae. Science 2002; 298:129-149.
3. Butler D. What difference does a genome make? Nature 2002; 419:426-428.
4. World Health Organization. Mental health: new understanding, new hope. Geneva: WHO; 2001.
5. Teklehaimanot A, Snow RW. Will the Global Fund help roll back malaria in Africa? Lancet 2002; 360:888-889. This editorial gives a cynical review of the potential impact of the Global Fund, suggesting that the support, particularly in the support of antimalaria actions, is paltry given the needs of Africa.
6. Greenwood B, Mutabingwa T. Malaria in 2002. Nature 2002; 415:670-672. This study provides a comprehensive overview of the current epidemiological trends, including the factors contributing to the increasing burden of malaria and potential causes. It reviews the new developments in methods for malaria control and in tabular format puts forward logical and practical methods of tackling the problem of apparently poor malaria control.
7. Guerin PJ, Olliaro P, Nosten F, et al. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis 2002; 2:564-573. This article stems from work developed by the Drugs for Neglected Diseases (DND) Working Group, an independent interdisciplinary working group (from academics, international and national institutions, and the pharmaceutical industry) established by Médecins Sans Frontières in the framework of the Campaign for Access to Essential Medicines. It maps out a research agenda to tackle failing malaria control and a global increase in malaria disease.
8. Kochar DK, Shubhakaran, Kumawat BL, et al. Cerebral malaria in Indian adults: a prospective study of 441 patients from Bikaner, north-west India. J Assoc Physicians India 2002; 50:234-241.
9. Romi R, Razaiarimanga MC, Raharimanga R, et al. Impact of the malaria control campaign (1993-1998) in the highlands of Madagascar: parasitological and entomological data. Am J Trop Med Hyg 2002; 66:2-6. A report on the re-appearance of malaria at the end of the 1980s after previous control in the 1960s as a result of a national control programme that used DDT indoor spraying and mass treatment with chloroquine. Yearly residual house spraying performed for 5 years (1993-1998) reduced the abundance of Anopheles funestus plus the availability of antimalarial drugs reduced malaria transmission to very low levels.
10. Hay SI, Cox J, Rogers DJ, et al. Climate change and the resurgence of malaria in the East African highlands. Nature 2002; 415:905-909. A very comprehensive study examining the long-term meteorological trends, including temperature, rainfall, vapour pressure and the number of months suitable for P. falciparum transmission are examined in four high-altitude sites in East Africa. They show that these have not changed significantly during the past century or during the period of reported malaria resurgence. Therefore, the claimed associations between local malaria resurgences and global warming are overly simplistic.
11. Shanks GD, Hay SI, Stern DI, et al. Meteorologic influences on Plasmodium falciparum malaria in the Highland Tea Estates of Kericho, Western Kenya. Emerg Infect Dis 2002; 8:1404-1408. A continuous 30-year monthly malaria incidence dataset (1966-1995) from hospital registers at a Kenyan tea plantation and contemporary monthly meteorological data (1966-1995) from the tea estate meteorological station and from global climatology records were tested for trends. They concluded that whereas malaria admission incidence increased the changes were not attributable to climate changes in western Kenya.
12. Winstanley P. Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria. Trop Med Int Health 2001; 6:952-954.
13. Olliaro P, Taylor WR, Rigal J. Controlling malaria: challenges and solutions. Trop Med Int Health 2001; 6:922-927.
14. Croft A. Extracts from 'Clinical Evidence'. Malaria: prevention in travellers. BMJ 2000; 321: 154-160.
15. Muentener P, Schlagenhauf P, Steffen R. Imported malaria (1985-95): trends and perspectives. Bull WHO 1999; 77: 560-566.
16. Stoppacher R, Adams SP. Malaria deaths in the United States: case report and review of deaths, 1979-1998. J Forens Sci 2003; 48:404-408. Epidemiological data are presented on 40 deaths (provided by the CDC) between 1992 and 1998.Thirty-eight (95%) of these were caused by P. falciparum and two (5%) were caused by Plasmodium vivax. Anti-malarial chemoprophylaxis was taken in 40% of cases. Twenty-four of the cases (60%) involved US travellers to endemic areas (59% to sub-Saharan Africa, 25% to South America, 8% to India, and 4% to Haiti), 28% involved foreign travellers to the US and three were induced cases (7.5%).
17. Jelinek T, Schulte C, Behrens R, et al. Imported falciparum malaria in Europe: sentinel surveillance data from the European network on surveillance of imported infectious diseases. Clin Infect Dis 2002; 34:572-576. This reports on the sentinel surveillance of data collected prospectively since 1999 by TropNetEurop, a European network focusing on imported infectious diseases.
18. Bruneel F, Hocqueloux L, Alberti C, et al. The clinical spectrum of severe imported falciparum malaria in the intensive care unit: report of 188 cases in adults. Am J Respir Crit Care Med 2003; 167:684-689. This is the largest retrospective study published to date of imported severe malaria describing the clinical spectrum and factors associated with fatal outcome in adults. It included 188 patients admitted to an intensive care unit in Paris between 1988-1999. Among them, 93 had strictly defined severe malaria. Nearly all infections (94%) were acquired in sub-Saharan Africa.
19. White N. Editorial. Am J Respir Crit Care Med 2003; 167:673-674.
20. Croft A, Garner P. Mefloquine to prevent malaria: a systematic review of trials. BMJ 1997; 315:1412-1416.
21. Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001; 33:1015-1021.
22. World Health Organization, Division of Control of Tropical Diseases. Severe and complicated malaria. Trans R Soc Trop Med Hyg 1990; 84 (Suppl. 2):S1-S65.
23. Newton CR, Krishna S. Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. Pharmacol Ther 1998; 79:1-53.
24. World Health Organization, Communicable Diseases Cluster. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000; 94 (Suppl. 1):S1-90.
25. Day NP, Phu NH, Bethell DP, et al. The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. Lancet 1996; 348:219-223.
26. Maitland K, Levin M, English M, et al. Severe P. falciparum malaria in Kenyan children: evidence for hypovolaemia. OJ Med 2003; 96: in press.
27. o 55 min) were lower in patients with severe malaria than in those with moderately severe malaria. There were no significant differences in the other metabolite increments (alanine, lactate and pyruvate; P=0.27).
28. Planche T, Dzeing A, Emmerson AC, et al Plasma glutamine and glutamate concentrations in Gabonese children with Plasmodium falciparum infection. Q J Med 2002; 95:89-97. A prospective study of 239 Gabonese children with mild or severe malaria and healthy controls. Plasma glutamine was lower in uncomplicated falciparum malaria than in healthy controls; and within the normal range in those with severe malaria and in febrile control children. Plasma glutamine was significantly higher in the children who died with malaria than in survivors.
29. White VA, Lewallen S, Beare N, et al. Correlation of retinal haemorrhages with brain haemorrhages in children dying of cerebral malaria in Malawi. Trans R Soc Trop Med Hyg 2001; 95:618-621.
30. Brown HC, Chau TT, Mai NT, et al. Blood-brain barrier function in cerebral malaria and CNS infections in Vietnam. Neurology 2000; 55:104-111.
31. Brown H, Rogerson S, Taylor T, et al. Blood-brain barrier function in cerebral malaria in Malawian children. Am J Trop Med Hyg 2001; 64:207-213.
32. Brown H, Hien TT, Day N, et al. Evidence of blood-brain barrier dysfunction in human cerebral malaria. Neuropathol Appl Neurobiol 1999; 25:331-340.
33. Adams S, Brown H, Turner G. Breaking down the blood-brain barrier: signaling a path to cerebral malaria? Trends Parasitol 2002; 18:360-366. The latest evidence from post-mortem, in-vitro and animal studies is reviewed in this paper, which highlights the role of BBB breakdown in cerebral malaria. BBB integrity is disturbed during severe malaria, causing leakage of cerebral vessels. This may have major implications for the treatment of severe malaria, in particular the role of neuroprotective therapies and the potential for cerebral oedema in children given volume replacement (see Ref. 36).
34. White NJ. Not much progress in treatment of cerebral malaria. Lancet 1998; 352:594-595.
35. Day NP, Phu NH, Mai NT, et al. Effects of dopamine and epinephrine infusions on renal hemodynamics in severe malaria and severe sepsis. Crit Care Med 2000; 28:1353-1362.
36. Maitland K, Pamba A, Newton C, Levin M. Response to volume resuscitation in children with severe malaria. Pediatr Crit Care Med 2003; in press.
37. Agbenyega T, Planche T, Bedu-Addo G, et al. Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children. J Clin Pharmacol 2003; 43:386-396. The authors describe the in-vitro pharmacokinetics of a single infusion of 50 mg/kg dichloroacetate. Dichloroacetate significantly increased the initial rate and magnitude of the fall in blood lactate levels and did not interfere with the plasma kinetics of quinine.
38. Zhang H, Spapen H, Nguyen DN, et al. Protective effects of N-acetyl-L-cysteine in endotoxemia. Am J Physiol 1994; 266:H1746-H1754.
39. Gruarin P, Primo L, Ferrandi C, et al. Cytoadherence of Plasmodium falciparum-infected erythrocytes is mediated by a redox-dependent conformational fraction of CD36. J Immunol 2001; 167:6510-6517.
40. Watt G, Jongsakul K, Ruangvirayuth R. A pilot study of N-acetylcysteine as adjunctive therapy for severe malaria. Q J Med 2002; 95:285-290. Phase I and II trials demonstrating a more rapid correction of lactic acidosis by N-acetylcysteine than placebo in adults with severe malaria. Trials of N-acetylcysteine adjunctive therapy for complicated malaria, with mortality as an endpoint, are warranted.
41. Rank N, Michel C, Haertel C, et al. N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study. Crit Care Med 2000; 28:3799-3807.
42. Dondorp AM, Angus BJ, Hardeman MR, et al. Prognostic significance of reduced red blood cell deformability in severe falciparum malaria. Am J Trop Med Hyg 1997; 57:507-511.
43. Dondorp AM, Kager PA, Vreeken J, White NJ. Abnormal blood flow and red blood cell deformability in severe malaria. Parasitol Today 2000; 16:228-232.
44. Dondorp AM, Nyanoti M, Kager PA, et al. The role of reduced red cell deformability in the pathogenesis of severe falciparum malaria and its restoration by blood transfusion. Trans R Soc Trop Med Hyg 2002; 96:282-286. An important study that shows that decreased RCDs of non-parasitized red cells are important in the pathophysiology of severe malaria anaemia complicated by lactic acidosis. RCD on admission was reduced in proportion to the severity of disease.
45. Ogutu BR, Newton CR, Crawley J, et al. Pharmacokinetics and anti-convulsant effects of diazepam in children with severe falciparum malaria and convulsions. Br J Clin Pharmacol 2002; 53:49-57. Plasma diazepam concentrations were measured in children receiving diazepam intravenously (0.3 mg/kg) or rectally (0.5 mg/kg). Therapeutic concentrations of diazepam were reached in all those given parenteral diazepam but only six out of nine of those receiving rectal diazepam. The control of seizures was more variable in children given rectal diazepam.
46. Newton CR, Hien TT, White N. Cerebral malaria. J Neurol Neurosurg Psychiatry 2000; 69:433-441.
47. White NJ, Looareesuwan S, Phillips RE, et al. Single dose phenobarbitone prevents convulsions in cerebral malaria. Lancet 1988; 2:64-66.
48. Crawley J, Waruiru C, Mithwani S, et al. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study. Lancet 2000; 355:701-706.
49. Ogutu BR, Newton CR, Muchohi SN, et al. Pnenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration. Br J Clin Pharmacol 2002; 54:635-642. The concomitant administration of chloramphenicol and a single intramuscular dose of fosphenytoin alters the half-life but not the other pharmacokinetic parameters or clinical effects of phenytoin in African children with severe malaria.
50. Ogutu BR, Newton CR, Muchohi SN, et al. Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with falciparum malaria and status epilepticus. Br J Clin Pharmacol 2003; 55: in press.
51. Gyr K, Speck B, Ritz R, et al. Cerebral tropical malaria with blackwater fever. A current diagnostic and therapeutic problem. Schweiz Med Wochenschr 1974; 104:1628-1630.
52. Macallan DC, Pocock M, Robinson GT, et al. Red cell exchange, erythrocytapheresis, in the treatment of malaria with high parasitaemia in returning travellers. Trans R Soc Trop Med Hyg 2000; 94:353-356.
53. Riddle MS, Jackson JL, Sanders JW, Blazes DL. Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: a meta-analysis. Clin Infect Dis 2002; 34:1192-1198. This analysis included studies that compared patients who received adjunct ET with patients who received antimalarial chemotherapy alone for the years 1966-2001. However, there were a number of methodological problems as patients treated with ET were significantly more critically ill; they met a greater number of WHO criteria for severe malaria and had higher levels of parasitaemia than patients who did not receive transfusions, which casts serious doubts on the conclusion of the study.
54. Graves P, Gelband H. Vaccines for preventing malaria. Cochrane Database Syst Rev 2003 1:CD000129. A meta-analysis of all malaria vaccine trials to date.
55. Herrington D, Davis J, Nardin E, et al. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg 1991; 45:539-547.
56. Pombo DJ, Lawrence G, Hirunpetcnarat C, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002; 360:610-617. Novel evidence of a direct role for cellular immunity in blood stage immunity.
57. Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997; 336:86-91.
58. Bojang KA, Milligan PJ, Pinder M, et al. Efficacy of RTS,S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001; 358:1927-1934.
59. Birkett A, Lyons K, Schmidt A, et al. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect Immun 2002; 70:6860-6870.
60. Le TP, Coonan KM, Hedstrom RC, et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000; 18:1893-1901.
61. McConkey SRW, Moorthy V, Webster D, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003 (in press)
62. Genton B, Betuela I, Felger I, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002; 185:820-827. Useful data on parasite allele selection in the absence of an overall effect.
63. Druilhe PSF, Corradin G, Audran R, et al. Safety and immunogenicity of the merozoite surface protein 3 antigen in phase 1 trials and assessment of the biological effect of the antibodies induced. In: MIM Conference, 2002. Arusha, Tanzania, December 2003.
64. Leach A, Stoute J, Wither M, et al. Double-blind, randomized safety and immunogenicity trial of P. falciparum MSP 1 adjuvanted in ASO2A vs rabies vaccine in malaria experienced adults in western Kenya. In: MIM Conference, 2002. Arusha, Tanzania, December 2002.
65. Sauerwein RTD, Verhage D, Theisen M. Assessment of the safety of a long synthetic peptide derived from Plasmodium falciparum GLURP in a phase 1 clinical trial. In: MIM Conference, 2002. Arusha, Tanzania, December 2002.
66. Angus BJ. Malaria on the World Wide Web. Clin Infect Dis 2001; 33:651-661.